DexCom (DXCM) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

DexCom

NasdaqGS•Healthcare•Medical Devices

$84.36-0.40(<0.01%)Market open

Market Cap

$31.61B

P/E

31.9x

P/S

6.2x

P/B

12.5x

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

How this company scores

ExcellentMetricSide Score: 84/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality21/25

Strengths

Strong marginsHigh ROERising earningsInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 31.9x5y range 25.6x – 339.1x

Currently below its 20-quarter median.

P/S · 6.2x5y range 4.9x – 21.4x

Currently below its 20-quarter median.

P/B · 12.5x5y range 8.1x – 24.0x

Price & Volume

Market Cap $31.61B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.10B
Q. Revenue: $1.34B
TTM EBITDA: $1.50B
TTM Op. Income: $1.22B
Q. Op. Income: $327.20M
TTM Net Income: $991.00M
Q. Net Income: $275.10M
EPS: $0.73
Shares Out.: $374.70M

$5.10B in TTM revenue grew 13.0% YoY, reaching $1.34B last quarter. TTM EBITDA of $1.50B and TTM operating income of $1.22B show growth is flowing through to the bottom line. TTM net income of $991.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.3%
EBITDA Margin: 29.9%
Op. Margin: 24.3%
Net Margin: 20.5%

Op. margin of 24.3% is up 4.3% YoY — cost efficiency is improving. Net margin at 20.5% and gross margin of 64.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 31.9x
P/S Ratio: 6.2x
P/B Ratio: 12.5x

At 31.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.2x and P/B of 12.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $6.24B
Cash: $961.40M
Long-Term Debt: N/A
Book Value: $2.54B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $325.60M
TTM Free Cash Flow: $1.10B
FCF Margin: 21.5%
FCF / Net Income: 1.1

TTM FCF of $1.10B on $325.60M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.